HRMY Q3 2020 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M

Gross Profit

$38M82.7% margin

Operating Income

$10M22.8% margin

Net Income

$2M4.2% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+20.0%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$320M

Total Liabilities

$226M

Stockholders' Equity

$95M

Cash & Equivalents

$222M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$0	—
Gross Profit	$38M	$0	—
Operating Income	$10M	-$30M	+134.8%
Net Income	$2M	-$32M	+106.0%